CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin

다국어 초록 (Multilingual Abstract)

Background: It is highly desirable to develop new therapeutic strategies for gastric cancer given the low survival rate despite improvement in the past decades. Cadherin 17 (CDH17) is a membrane protein highly expressed in cancers of digestive system. Nanobody represents a novel antibody format for cancer targeted imaging and drug delivery. Nanobody targeting CHD17 as an imaging probe and a delivery vehicle of toxin remains to be explored for its theragnostic potential in gastric cancer. Methods: Naïve nanobody phage library was screened against CDH17 Domain 1-3 and identified nanobodies were extensively characterized with various assays. Nanobodies labeled with imaging probe were tested in vitro and in vivo for gastric cancer detection. A CDH17 Nanobody fused with toxin PE38 was evaluated for gastric cancer inhibition in vitro and in vivo. Results: Two nanobodies (A1 and E8) against human CDH17 with high affinity and high specificity were successfully obtained. These nanobodies could specifically bind to CDH17 protein and CDH17-positive gastric cancer cells. E8 nanobody as a lead was extensively determined for tumor imaging and drug delivery. It could efficiently co-localize with CDH17-positive gastric cancer cells in zebrafish embryos and rapidly visualize the tumor mass in mice within 3 h when conjugated with imaging dyes. E8 nanobody fused with toxin PE38 showed excellent anti-tumor effect and remarkably improved the mice survival in cell-derived (CDX) and patient-derived xenograft (PDX) models. The immunotoxin also enhanced the anti-tumor effect of clinical drug 5-Fluorouracil. Conclusions: The study presents a novel imaging and drug delivery strategy by targeting CDH17. CDH17 nanobodybased immunotoxin is potentially a promising therapeutic modality for clinical translation against gastric cancer.

참고문헌 (Reference)

1 Kijanka M, "Van Bergen En Henegouwen PM : rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs sitedirectly conjugated to IRDye 800CW for image-guided surgery" 40 (40): 1718-1729, 2013

2 Panarelli NC, "Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2" 138 (138): 211-222, 2012

3 Li N, "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma" 114 (114): 6623-6631, 2017

4 Wang J, "The predictive effect of cadherin-17 on lymph node micrometastasis in pN0 gastric cancer" 19 (19): 1529-1534, 2012

5 Janjigian YY, "The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer" 600 (600): 727-730, 2021

6 Liu LX, "Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma" 50 (50): 1453-1463, 2009

7 Lin Z, "Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer" 9 (9): 85296-, 2014

8 Kusano-Arai O, "Synergistic cytotoxic effect on gastric cancer cells of an immunotoxin cocktail in which antibodies recognize different epitopes on CDH17" 37 (37): 1-11, 2018

9 Kreitman RJ, "Study i : Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia(HCL) : long-term follow-up from the pivotal trial" 14 (14): 35-, 2021

10 Koenig PA, "Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape" 371 (371): 6230-, 2021

11 Chalabi M, "Stomach cancer gets a triple punch of therapy" 600 (600): 608-609, 2021

12 Misumi T, "Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer" 13 (13): 0204880-, 2018

13 Debie P, "Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours" 317 : 34-42, 2020

14 Tian X, "Silencing of cadherin-17enhances apoptosis and inhibits autophagy in colorectal cancer cells" 108 : 331-337, 2018

15 Garcia-Martinez JM, "Selective tumor cell apoptosis and tumor regression in CDH17-positive colorectal cancer models using BI 905711, a novel liver-sparing TRAILR2 agonist" 20 (20): 96-108, 2021

16 Krasniqi A, "Same-day imaging using small proteins : clinical experience and translational prospects in oncology" 59 (59): 885-891, 2018

17 Wei J, "Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity" 115 (115): 3501-3508, 2018

18 Lwin TM, "Rapid tumor-labeling kinetics with a site-specific near-infrared anti-CEA nanobody in a patient-derived orthotopic xenograft mouse model of colon cancer" 124 (124): 1121-1127, 2021

19 Casal JI, "RGD cadherins and alpha2beta1 integrin in cancer metastasis : a dangerous liaison" 1869 (1869): 321-332, 2018

20 Keyaerts M, "Phase I study of 68Ga-HER2-Nanobody for PET/CT assessment of HER2 expression in breast carcinoma" 57 (57): 27-33, 2016

21 Abdolahi S, "Patient-derived xenograft(PDX)models, applications and challenges in cancer research" 20 (20): 206-, 2022

22 Jailkhani N, "Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix" 116 (116): 14181-14190, 2019

23 Liang M, "Near-infrared fluorescence-guided resection of micrometastases derived from esophageal squamous cell carcinoma using a c-met-targeted probe in a preclinical xenograft model" 332 : 171-183, 2021

24 Bao G, "Nanobody : a promising toolkit for molecular imaging and disease therapy" 11 (11): 6-, 2021

25 Verhaar ER, "Nanobodies in cancer" 52 : 101425-, 2021

26 Harmand TJ, "Nanobodies as in vivo, noninvasive, imaging agents" 2 (2): 685-701, 2021

27 Panikar SS, "Nanobodies as efficient drug-carriers : progress and trends in chemotherapy" 334 : 389-412, 2021

28 Muyldermans S, "Nanobodies : natural single-domain antibodies" 82 : 775-797, 2013

29 Bartolome RA, "Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis" 24 (24): 433-444, 2018

30 Reddavid R, "Molecularly targeted therapies for gastric cancer. State of the art" 13 (13): 4094-, 2021

31 Yui A, "Mechanism of dimerization and structural features of human LI-cadherin" 297 (297): 101054-, 2021

32 Shiraishi K, "Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity" 16 (16): 571-580, 2013

33 Li R, "Inhibition of CDH17 gene expression via RNA interference reduces proliferation and apoptosis of human MKN28 gastric cancer cells" 50 (50): 15-22, 2017

34 Khirehgesh MR, "Immunotoxins and nanobodybased immunotoxins : review and update" 29 (29): 848-862, 2021

35 Gao W, "Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis" 6 : 6536-, 2015

36 Mazor R, "Immunogenicity of Immunotoxins containing Pseudomonas exotoxin a : causes, consequences, and mitigation" 11 : 1261-, 2020

37 Li T, "Immuno-targeting the multifunctional CD38 using nanobody" 6 : 27055-, 2016

38 Iida K, "Identification and therapeutic targeting of GPR20, selectively expressed in gastrointestinal stromal tumors, with DS-6157a, a firstin-class antibody-drug conjugate" 11 (11): 1508-1523, 2021

39 Gravalos C, "HER2 in gastric cancer : a new prognostic factor and a novel therapeutic target" 19 (19): 1523-1529, 2008

40 Lee HJ, "Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer" 139 (139): 213-225, 2010

41 Snow AN, "Expression of cadherin 17 in well-differentiated neuroendocrine tumours" 66 (66): 1010-1021, 2015

42 Yang E, "Engineering nanobodies for nextgeneration molecular imaging" 27 (27): 1622-1638, 2022

43 van Driel P, "EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer" 229 : 93-105, 2016

44 Liu X, "Disruption of oncogenic liver-intestine cadherin(CDH17)drives apoptotic pancreatic cancer death" 454 : 204-214, 2019

45 Wang J, "Disrupting circadian rhythm via the PER1-HK2 axis reverses trastuzumab resistance in gastric cancer" 82 (82): 1503-1517, 2022

46 Fleming BD, "Development of Glypican-3 targeting Immunotoxins for the treatment of liver Cancer : an update" 10 (10): 934-, 2020

47 Hu G, "Development and comparison of three (89)Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study" 49 (49): 2634-2644, 2022

48 Joshi SS, "Current treatment and recent progress in gastric cancer" 71 (71): 264-279, 2021

49 Lum YL, "Cadherin-17 targeted near-infrared photoimmunotherapy for treatment of gastrointestinal cancer" 17 (17): 3941-3951, 2020

50 Bartolome RA, "Cadherin-17 interacts with alpha2beta1 integrin to regulate cell proliferation and adhesion in colorectal cancer cells causing liver metastasis" 33 (33): 1658-1669, 2014

51 Nakamura Y, "Biomarkertargeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers : an emerging paradigm" 18 (18): 473-487, 2021

52 Dijkers EC, "Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer" 87 (87): 586-592, 2010

53 Casal JI, "Beyond N-cadherin, relevance of cadherins 5, 6 and 17 in cancer progression and metastasis" 20 (20): 3373-, 2019

54 Yoshida GJ, "Applications of patient-derived tumor xenograft models and tumor organoids" 13 (13): 4-, 2020

55 Wang Y, "Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma" 8 (8): 72386-, 2013

56 Schoof M, "An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive spike" 370 (370): 1473-1479, 2020

57 Kmeid M, "Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma : a pathological, clinical and outcome study" 79 (79): 768-778, 2021

58 Lopes N, "A panel of intestinal differentiation markers(CDX2, GPA33, and LI-cadherin)identifies gastric cancer patients with favourable prognosis" 23 (23): 811-823, 2020

59 Liu J, "A new mechanism of trastuzumab resistance in gastric cancer : MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway" 9 (9): 76-, 2016

60 Palmer AC, "A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity" 8 : 50036-, 2019

61 Asaadi Y, "A comprehensive comparison between camelid nanobodies and single chain variable fragments" 9 (9): 87-, 2021

62 Cao T, "A CGA/EGFR/GATA2 positive feedback circuit confers chemoresistance in gastric cancer" 132 (132): 154074-, 2022

63 Fujiwara K, "64Culabeled minibody D2101 visualizes CDH17-positive gastric cancer xenografts with short waiting time" 41 (41): 688-695, 2020

64 Fujiwara K, "(111)inlabeled anti-cadherin17 antibody D2101 has potential as a noninvasive imaging probe for diagnosing gastric cancer and lymph-node metastasis" 34 (34): 13-23, 2020